TheStreet Lowers AdaptHealth (NASDAQ:AHCO) to D+

AdaptHealth (NASDAQ:AHCOGet Rating) was downgraded by equities research analysts at TheStreet from a “c-” rating to a “d+” rating in a research report issued on Friday, TheStreetRatingsTable reports.

Other equities research analysts also recently issued reports about the stock. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of AdaptHealth from $34.00 to $28.00 in a research note on Friday, February 25th. Truist Financial dropped their price target on AdaptHealth from $30.00 to $20.00 in a research note on Friday, February 25th. Canaccord Genuity Group reduced their price objective on AdaptHealth from $44.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, February 25th. Zacks Investment Research lowered AdaptHealth from a “hold” rating to a “strong sell” rating in a research report on Wednesday, April 27th. Finally, Robert W. Baird reduced their price target on shares of AdaptHealth from $34.00 to $26.00 in a research report on Friday, February 25th. Two research analysts have rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $28.25.

AdaptHealth stock opened at $12.86 on Friday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.09 and a current ratio of 1.34. The stock has a market cap of $1.70 billion, a PE ratio of 32.97, a price-to-earnings-growth ratio of 0.22 and a beta of 0.47. The stock has a 50-day moving average of $15.76 and a two-hundred day moving average of $19.63. AdaptHealth has a one year low of $12.40 and a one year high of $30.33.

AdaptHealth (NASDAQ:AHCOGet Rating) last posted its quarterly earnings data on Thursday, February 24th. The company reported $0.15 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.40 by ($0.25). The company had revenue of $702.11 million for the quarter, compared to analyst estimates of $693.15 million. AdaptHealth had a net margin of 6.36% and a return on equity of 7.97%. As a group, sell-side analysts predict that AdaptHealth will post 1.4 EPS for the current fiscal year.

In other news, CEO Stephen P. Griggs bought 32,342 shares of the stock in a transaction dated Thursday, March 3rd. The shares were acquired at an average cost of $15.44 per share, with a total value of $499,360.48. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Skyknight Capital Fund Ii, L.P purchased 25,000 shares of AdaptHealth stock in a transaction that occurred on Monday, March 14th. The stock was acquired at an average cost of $15.25 per share, with a total value of $381,250.00. The disclosure for this purchase can be found here. Insiders acquired 88,180 shares of company stock valued at $1,351,923 over the last three months. 17.30% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Dimension Capital Management LLC boosted its holdings in AdaptHealth by 43.1% in the 3rd quarter. Dimension Capital Management LLC now owns 100,790 shares of the company’s stock worth $2,347,000 after buying an additional 30,361 shares during the last quarter. OLD Mission Capital LLC acquired a new stake in shares of AdaptHealth in the third quarter worth approximately $2,027,000. Swiss National Bank increased its position in shares of AdaptHealth by 35.4% during the third quarter. Swiss National Bank now owns 171,300 shares of the company’s stock worth $3,990,000 after purchasing an additional 44,800 shares in the last quarter. Emerald Mutual Fund Advisers Trust raised its stake in AdaptHealth by 43.0% in the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 363,273 shares of the company’s stock valued at $8,886,000 after purchasing an additional 109,279 shares during the last quarter. Finally, Twinbeech Capital LP purchased a new position in AdaptHealth in the 3rd quarter valued at $797,000. 83.68% of the stock is currently owned by hedge funds and other institutional investors.

AdaptHealth Company Profile (Get Rating)

AdaptHealth Corp., together with its subsidiaries, provides home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps to patients for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.

Featured Articles

Analyst Recommendations for AdaptHealth (NASDAQ:AHCO)

Receive News & Ratings for AdaptHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AdaptHealth and related companies with MarketBeat.com's FREE daily email newsletter.